$576.42
0.67% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US75886F1075
Symbol
REGN

Regeneron Pharmaceuticals Stock price

$576.42
+3.83 0.67% 1M
+18.51 3.32% 6M
-135.91 19.08% YTD
-440.11 43.30% 1Y
-159.54 21.68% 3Y
-8.76 1.50% 5Y
+57.07 10.99% 10Y
+567.11 6,091.41% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+3.82 0.67%
ISIN
US75886F1075
Symbol
REGN
Industry

Key metrics

Basic
Market capitalization
$60.7b
Enterprise Value
$55.9b
Net debt
positive
Cash
$7.5b
Shares outstanding
106.4m
Valuation (TTM | estimate)
P/E
13.9 | 14.4
P/S
4.3 | 4.3
EV/Sales
3.9 | 4.0
EV/FCF
15.7
P/B
2.0
Financial Health
Equity Ratio
77.7%
Return on Equity
15.0%
ROCE
11.8%
ROIC
12.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$14.2b | $14.1b
EBITDA
$4.6b | $4.6b
EBIT
$4.1b | $4.4b
Net Income
$4.5b | $4.2b
Free Cash Flow
$3.6b
Growth (TTM | estimate)
Revenue
5.4% | -0.5%
EBITDA
-1.1% | -2.7%
EBIT
-2.6% | 3.7%
Net Income
3.2% | -4.0%
Free Cash Flow
11.7%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
32.2% | 32.4%
EBIT
28.6%
Net
31.4% | 30.0%
Free Cash Flow
25.0%
More
EPS
$41.1
FCF per Share
$33.4
Short interest
2.8%
Employees
15k
Rev per Employee
$940.0k
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

27x Buy
79%
6x Hold
18%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
79%
Hold
18%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14,214 14,214
5% 5%
100%
- Direct Costs 1,925 1,925
9% 9%
14%
12,290 12,290
5% 5%
86%
- Selling and Administrative Expenses 3,087 3,087
9% 9%
22%
- Research and Development Expense 5,120 5,120
9% 9%
36%
4,570 4,570
1% 1%
32%
- Depreciation and Amortization 510 510
13% 13%
4%
EBIT (Operating Income) EBIT 4,060 4,060
3% 3%
29%
Net Profit 4,459 4,459
3% 3%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
about 14 hours ago
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma
Positive
The Motley Fool
one day ago
One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing maxim goes, "Buy low, sell high.
Neutral
GlobeNewsWire
3 days ago
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,158
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today